# Radius Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/radius-health

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.radiuspharm.com
- Total disclosed funding: $237M
- Latest round: Series B (Apr 25, 2013)
- Investors on record: 11

## About

Radius Health, Inc. is a biopharmaceutical company focused on developing innovative therapies for bone health and related conditions, particularly osteoporosis treatment, through its advanced product offerings. Founded in 2003, Radius Health, Inc. is based in Boston, US, and specializes in biopharmaceuticals aimed at improving bone health. The company was established by Susan Hunter, and has since undergone strategic pivots to enhance its product lineup. Radius Health, Inc. completed a public to private transition in 2022, raising a total of USD 849.78 million from investors including Gurnet Point Capital and Patient Square Capital. Radius Health primarily focuses on developing innovative biopharmaceutical products that target bone health and related therapeutic areas. Their flagship product, TYMLOS® (abaloparatide) injection, was launched in the U.S. in 2017 and has received supplemental FDA approval to broaden its indications. TYMLOS® is designed to treat osteoporosis in postmenopausal women, serving a critical need in a population vulnerable to bone fractures. In 2023, the company expanded its product portfolio through the exclusive licensing of BINOSTO® (alendronate sodium), a once-weekly oral bisphosphonate indicated for osteoporosis treatment. Radius Health is committed to addressing the needs of underserved patient populations, with its products primarily marketed in the United States while also exploring opportunities for partnerships and expansion into additional geographical markets. The company generates revenue through the commercialization of its patented pharmaceutical products, particularly TYMLOS® and BINOSTO®. Their business model involves direct sales to healthcare providers, pharmacies, and hospitals, establishing a B2B transaction structure that facilitates access to its medications. Radius Health is planning to further develop and launch new product lines, including enhancements to its existing offerings. They are also focused on expanding their market presence internationally, targeting Europe and Asia by 2025. In March 2026, Radius Health, Inc., a portfolio company of Gurnet Point Capital and Patient Square Capital, merged with Paratek Pharmaceuticals, Inc., a portfolio company of Gurnet Point Capital. As part of the transaction, Sixth Street and Blackstone provided USD 1.3 billion in debt financing to support the merger.

## Funding rounds

- Series B, Apr 25, 2013, $43M — Brookside Capital Partners, BB Biotech, MPM BioImpact, F2 Ventures
- Series C, Feb 13, 2012, $21M — HealthCare Ventures, Saints Capital, Scottish Widows Investment Partnership, Brookside Capital Partners, BB Biotech, MPM BioImpact
- Series C, May 24, 2011, $66M — HealthCare Ventures, Wellcome Trust, Saints Capital, Scottish Widows Investment Partnership, Brookside Capital Partners, BB Biotech, MPM BioImpact, Ipsen Group, Nordic Bioscience A/S
- Series C, Nov 20, 2008, $15M — HealthCare Ventures, Oxford Bioscience Partners, Wellcome Trust, Scottish Widows Investment Partnership, BB Biotech, MPM BioImpact
- Series C, Mar 31, 2008, $28M — HealthCare Ventures, Oxford Bioscience Partners, BB Biotech, MPM BioImpact
- Series C, Aug 29, 2007, $9.9M — HealthCare Ventures, Oxford Bioscience Partners, MPM BioImpact
- Series C, Mar 8, 2007, $11M — HealthCare Ventures, Oxford Bioscience Partners, Wellcome Trust, Scottish Widows Investment Partnership, BB Biotech, MPM BioImpact
- Series C, Dec 15, 2006, $18M — HealthCare Ventures, Oxford Bioscience Partners, MPM BioImpact
- Series B, Dec 20, 2005, $8M — HealthCare Ventures, Oxford Bioscience Partners, MPM BioImpact
- Series B, Dec 31, 2004, $8M — HealthCare Ventures, Oxford Bioscience Partners, MPM BioImpact
- Series B, Nov 17, 2003, $8M — Oxford Bioscience Partners, MPM BioImpact

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- HealthCare Ventures — Series B, Series C
- Wellcome Trust — Series C
- Scottish Widows Investment Partnership (https://capitalatlas.ai/funds/scottish-widows-investment-partnership) — Series C
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series C, Series B
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series C
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series C, Series B
- Ipsen Group — Series C
- Nordic Bioscience A/S — Series C
- F2 Ventures (https://capitalatlas.ai/funds/f2-ventures) — Series B